MALVERN, Pa., April 4, 2022 /PRNewswire/ — Response Biology (“Reaction” or the “Corporation”), an sector-leading supplier of drug discovery solutions, these days introduced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Main Business Officer (CBO) and member of the Executive Committee, powerful promptly, to further bolster the leadership staff and aid the Company’s following phase of growth.
“We are thrilled to welcome Prosperous, a seasoned health care finance and operations govt, to the Executive Committee of Reaction Biology,” said John H. Johnson, Chief Executive Officer and Director of Reaction Biology. “Having managed huge, world-wide biopharmaceutical and life sciences companies in excess of the study course of his occupation, Abundant provides priceless expertise and insights to Response in our Firm’s evolution as a environment leader in drug discovery companies.”
Mr. Kollender has additional than 30 many years of experience in the healthcare sector. Prior to joining Response Biology, he served as Strongbridge BioPharma’s President and Main Economical Officer and was liable for strengthening the company’s financial placement and footprint as a successful exceptional sickness organization until eventually it was acquired by Xeris Biopharma, Inc., in October 2021. From 2003, he served 1st as a Principal and then as Companion of Quaker Associates Administration, LP, a healthcare expense organization. In addition, from August 2016 by way of September 2018, he served as Main Organization Officer and Chief Monetary Officer of Rapid Micro Biosystems, a Quaker Partners’ portfolio company, where he performed a essential job in the company enlargement and adoption of the company’s Development Direct™ Method. Earlier, he held positions in sales, marketing, and around the globe business enterprise development at GlaxoSmithKline (GSK) and served as investment decision manager at its corporate venture cash arm, S.R. A single. He commenced his career as a Licensed General public Accountant, originally with KPMG. He presently serves as Chairman of the Board of Administrators for Restorative Therapies. He also serves on the Board of Administrators for Immediate Micro Biosystems (NASDAQ: RPID) and as an adjunct faculty member at Lehigh University. He formerly served on the Board of Directors of Strongbridge BioPharma, Insmed, NuPathe, Inc., and Celator Pharmaceuticals, Inc., in addition to various other privately held businesses. He retains an MBA and a certificate diploma in the graduate program in health administration and coverage, both of those from the University of Chicago and a B.A. in accounting from Franklin and Marshall Faculty.
“Reaction Biology is moving into a pivotal period in its advancement as a most well-liked companion to biopharmaceutical businesses in the thrilling and ever-shifting location of drug discovery,” said Richard S. Kollender. “I look forward to drawing from my corporate finance and company operations knowledge to supply worth to our buyers, as perfectly as the service provider and affected individual communities who request secure and productive therapeutic innovations.”
About Reaction Biology
Founded in 2001, Response is a agreement study business (CRO) that presents a entire suite of drug discovery services to about 1,800 biopharmaceutical customers globally. Reaction’s abilities include functional biochemical assays, compound screening, a extensive selection of mechanistic and biophysical experiments, and an substantial array of cell-dependent assays. Reaction maintains just one of the biggest panels of kinase assays in the earth with more than 750 one of a kind assays. The Firm performs more than 5,000 consumer initiatives on a yearly basis with its around 2,000 validated assays. The Business has lab amenities in Malvern, PA, and Freiburg, Germany, with roughly 130 employees.
Elixir Overall health General public Relations
Resource Response Biology